Galapagos receives transparency notification from Wellington Management Group LLP
February 01 2016 - 4:40PM
Pursuant to Belgian transparency legislation[1], Galapagos received
a transparency notification on 28 January 2016 from Wellington
Management Group LLP, who notified that the 2,168,093 Galapagos
shares held by its entirely-controlled subsidiary Wellington
Management Company LLP on 19 January 2016 represent 4.73% of the
current 45,837,043 outstanding Galapagos shares as a result of
Galapagos' most recent capital increase. Wellington
Management Group LLC's shareholding thus passively decreased below
the lowest 5% threshold of Galapagos' voting rights. This is
the second transparency notice received from Wellington Management
Group LLP, reporting an increased number of shares held since the
first notice. The full transparency notice is available for
viewing on the Galapagos website.
About Galapagos Galapagos (Euronext &
NASDAQ: GLPG) is a clinical-stage biotechnology company specialized
in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises two Phase 2,
four Phase 1, five pre-clinical, and 20 discovery studies in cystic
fibrosis, inflammation, fibrosis, osteoarthritis and other
indications. We have discovered and developed filgotinib: in
collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the
world. Galapagos is focused on the development and
commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 400 employees, operating from
its Mechelen, Belgium headquarters and facilities in The
Netherlands, France, and Croatia. More information at
www.glpg.com.
CONTACT
Investors: Media:
Elizabeth
Goodwin Evelyn
Fox VP IR & Corporate
Communications Director
Communications +1 781 460
1784
+31 6 53 591 999
ir@glpg.com
communications@glpg.com
Galapagos Forward-Looking
Statements This release may contain forward-looking
statements. Galapagos cautions the reader that
forward-looking statements are not guarantees of future
performance. Forward-looking statements involve known and
unknown risks, uncertainties and other factors which might cause
the actual results, financial condition and liquidity, performance
or achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by
such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity,
and the development of the industry in which it operates are
consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods.
Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical
trial and product development activities and regulatory approval
requirements, Galapagos' reliance on collaborations with third
parties, and estimating the commercial potential of our product
candidates. A further list and description of these risks,
uncertainties and other risks can be found in the company's
Securities and Exchange Commission filing and reports, including in
the company's prospectus filed with the Securities and Exchange
Commission on May 14, 2015 and subsequent filings and reports filed
by the company with the Securities and Exchange Commission.
Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These
forward-looking statements speak only as of the date of publication
of this document. Galapagos expressly disclaims any
obligation to update any such forward-looking statements in this
document to reflect any change in its expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statement is based or that may affect the likelihood
that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
[1] Belgian Act of 2 May 2007 on the disclosure
of major shareholdings in issuers whose shares are admitted to
trading on a regulated market
Galapagos receives transparancy notification from Wellington
http://hugin.info/133350/R/1982797/726566.pdf
HUG#1982797
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024